SCHEMBL2178230

SCHEMBL2178230

CNc1nccc(-c2cc(NCCCBr)c3cc(OC)ccc3c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.43
ADRA1D P25100 3/20 0.43
ADRA1A P35348 3/20 0.43
ADRA1B P35368 3/20 0.43
PIK3CG P48736 5/20 0.40
PIK3CB P42338 4/20 0.40
PIK3CA P42336 4/20 0.40
DYRK1A Q13627 4/20 0.40
CLK4 Q9HAZ1 4/20 0.40
DYRK1B Q9Y463 3/20 0.40
CLK1 P49759 3/20 0.40
CLK2 P49760 2/20 0.40
MKNK1 Q9BUB5 3/20 0.37
FERMT2 Q96AC1 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ACP1 P24666 1/20 0.37
FLT3 P36888 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
CDK5 Q00535 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177838 0.90 FERMT2 (0.44) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2177415 0.86 HTR1A (0.40) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2176324 0.85 MKNK1 (0.43) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2176538 0.83 HTR1A (0.38) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2176544 0.82 HTR1A (0.37) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2177982 0.82 MEN1 (0.43) MKNK1MEN1KMT2AACP1MKNK2
SCHEMBL2178808 0.81 CASP2 (0.41) PIK3CGPIK3CBPIK3CADYRK1ACLK4
SCHEMBL2178975 0.81 SYK (0.37) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2177942 0.80 PDPK1 (0.36) HTR1AADRA1DADRA1AADRA1BPIK3CG
SCHEMBL2678111 0.80 MTNR1A (0.40) PIK3CGPIK3CBPIK3CADYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US claimed
EP-2519519-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
US-8173808-B2 Substituted naphthalenyl-pyrimidine compounds ARQULE, INC. (US) 2012-05-08 US disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
WO-2011082268-A2 SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS ARQULE INC. (US) 2011-07-07 WO disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds ARQULE, INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166137-A1 Substituted Naphthalenyl-Pyrimidine Compounds DPYD, TP53, TYMP HTR1A 2434/4885ADRA1D 3999/4885ADRA1A 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.